Orphenadrine Hydrochloride

盐酸奥芬那君

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameOrphenadrine Hydrochloride
Drug Alias Nameorphenadrinum奥芬那君盐酸盐orfenadrina盐酸邻甲苯海拉明Disipal +[7] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionMuscarinic acetylcholine receptor antagonists
TargetsMuscarinic acetylcholine receptor
Therapy Area/IndicationsParkinson DiseaseMusculoskeletal Pain
Global Approved IndicationsParkinson DiseaseMusculoskeletal Pain
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date1957/05/10
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusWithdrawn
Highest Status in ChinaN/A
Originator Companies3m
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive Companies3m Healthcare Ltd
Active IndicationsN/A
Inactive IndicationsParkinson DiseaseMusculoskeletal Pain

Other Information

ATC CodeN04AB02
Related LinksWikipediaDrugBankKEGG